Emerging treatments for viral retinitis

Mostafa A. Nokta, Stephen G. Hausrath, Richard B Pollard

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Cytomegalovirus is the most frequent cause of viral retinitis. It rarely causes disease in immunocompetent individuals, but is an important cause of retinitis in immunocompromised patients. Therapy with ganciclovir or foscarnet may result in a decrease in the morbidity related to cytomegalovirus, but problems with drug toxicity and development of clinical and viral resistance mandate additional therapeutic approaches. Preliminary phase I/II clinical trials suggest that human neutralising monoclonal antibodies to cytomegalovirus plus ganciclovir or foscarnet may be more effective than either ganciclovir or foscarnet alone for treating cytomegalovirus retinitis and in prolonging the time to cytomegalovirus disease progression in patients with AIDS. An approach based on an antisense oligonucleotide complementary to cytomegalovirus messenger RNA also shows promise.

Original languageEnglish (US)
Pages (from-to)423-432
Number of pages10
JournalBioDrugs
Volume7
Issue number6
StatePublished - 1997
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Emerging treatments for viral retinitis'. Together they form a unique fingerprint.

  • Cite this

    Nokta, M. A., Hausrath, S. G., & Pollard, R. B. (1997). Emerging treatments for viral retinitis. BioDrugs, 7(6), 423-432.